SELLAS Life Sciences Group Future Growth

Future criteria checks 5/6

SELLAS Life Sciences Group is forecast to grow earnings and revenue by 60% and 67.2% per annum respectively while EPS is expected to grow by 60.6% per annum.

Key information

60.0%

Earnings growth rate

60.56%

EPS growth rate

Biotechs earnings growth	25.2%
Revenue growth rate	67.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 May 2026

Recent future growth updates

Recent updates

Analysis Article • Oct 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Jun 25

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Nov 23

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

SELLAS Life Sciences (NASDAQ:SLS) is trading 9.2% higher on Tuesday after the company announced results from preclinical studies for its CDK9 inhibitor, GFH009, to treat solid cancer and acute myeloid leukemia (AML) cell lines. The drug showed significant anti-tumor effects in all four selected cell lines, and in three out of the four cell lines, GFH009 inhibited cancer cell growth by 90% to 100%. The following cell lines were selected for the studies: RH30: a pediatric soft tissue sarcoma cell line. NCI-H209: a small cell lung cancer cell line. SKOV-3: an ovarian cancer cell line. OCI-AML-2: an AML cell line. "The data from preclinical studies that we are reporting today demonstrates that certain cancer cell lines, whose survival depends on specific changes in the cell, can be identified and treated with GFH009," said Dragan Cicic, Senior Vice President, Clinical Development, of SELLAS.

Earnings and Revenue Growth Forecasts

NasdaqCM:SLS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	102	N/A	N/A	N/A	1
12/31/2027	44	-47	N/A	N/A	1
12/31/2026	N/A	-37	N/A	N/A	1
3/31/2026	N/A	-29	-28	-28	N/A
12/31/2025	N/A	-27	-28	-28	N/A
9/30/2025	N/A	-26	-31	-31	N/A
6/30/2025	N/A	-26	-31	-31	N/A
3/31/2025	N/A	-27	-34	-34	N/A
12/31/2024	N/A	-31	-35	-35	N/A
9/30/2024	N/A	-32	-33	-33	N/A
6/30/2024	N/A	-34	-35	-32	N/A
3/31/2024	N/A	-36	-36	-30	N/A
12/31/2023	N/A	-37	-37	-31	N/A
9/30/2023	N/A	-38	-37	-32	N/A
6/30/2023	N/A	-36	-33	-31	N/A
3/31/2023	N/A	-36	-33	-29	N/A
12/31/2022	1	-41	-28	-24	N/A
9/30/2022	1	-39	-28	-24	N/A
6/30/2022	1	-39	-28	-24	N/A
3/31/2022	3	-35	-23	-23	N/A
12/31/2021	8	-21	-26	-26	N/A
9/30/2021	10	-18	-18	-18	N/A
6/30/2021	10	-15	-15	-15	N/A
3/31/2021	8	-15	-14	-14	N/A
12/31/2020	2	-17	-10	-10	N/A
9/30/2020	N/A	-21	-18	-18	N/A
6/30/2020	N/A	-28	-18	-18	N/A
3/31/2020	N/A	-27	-19	-19	N/A
12/31/2019	N/A	-28	N/A	-18	N/A
9/30/2019	N/A	-34	N/A	-18	N/A
6/30/2019	N/A	-32	N/A	-28	N/A
3/31/2019	N/A	-36	N/A	-30	N/A
12/31/2018	N/A	-41	N/A	-30	N/A
9/30/2018	N/A	-37	N/A	-28	N/A
6/30/2018	N/A	-32	N/A	-16	N/A
3/31/2018	N/A	-30	N/A	-13	N/A
12/31/2017	N/A	-24	N/A	-11	N/A
9/30/2017	N/A	-21	N/A	-14	N/A
6/30/2017	N/A	-23	N/A	-16	N/A
3/31/2017	N/A	-20	N/A	-14	N/A
12/31/2016	N/A	-18	N/A	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: SLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SLS is expected to become profitable in the next 3 years.

Revenue vs Market: SLS's revenue (67.2% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: SLS's revenue (67.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SLS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/17 12:06
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SELLAS Life Sciences Group, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Aydin Huseynov	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

SELLAS Life Sciences Group Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2028

No longer forecast to breakeven

Price target decreased by 17% to US$5.83

Consensus EPS estimates fall by 19%

Consensus EPS estimates upgraded to US$0.87 loss

Consensus EPS estimates fall by 12%

Recent updates

SELLAS Life Sciences Approaches Key AML Trial Results With Strengthened Cash Position and New Phase 2 Study

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 16, 2026

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Profitability

Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML

Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Forecast to breakeven in 2028

New minor risk - Share price stability

Independent Director recently bought US$101k worth of stock

Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 Programs

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without Modification

Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy Study

SELLAS Life Sciences Group, Inc. Appoints Linghua Wang to Scientific Advisory Board

New minor risk - Share price stability

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

New minor risk - Profitability

Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory Board

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AML

SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR Conference

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 17, 2025

SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual Meeting

SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.

New minor risk - Share price stability

Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML

SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Price target decreased by 17% to US$5.83

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

Consensus EPS estimates fall by 19%

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting